Entrada Therapeutics
About
Entrada Therapeutics is a Boston biotechnology company developing a new class of intracellular therapeutics, medicines designed to reach disease-causing targets inside cells that have been hard or impossible to drug. Its proprietary EEV platform is built to carry therapies into cells, and the company describes it as versatile and modular, with potential across many therapeutic areas. Duchenne muscular dystrophy, a genetic disease that progressively weakens muscles, is a central focus.
The pipeline spans discovery through clinical-stage programs in neuromuscular, retinal and metabolic diseases. Entrada shares patient stories such as that of Max, a boy with Duchenne whose family sought out clinical trials, to show why its work matters. The company is publicly traded on Nasdaq and reports quarterly financial results, and it recruits scientists and other staff who want to take on difficult technical challenges.
What to Know
- Entrada runs an annual DREAMS grant program, now in its fourth year.
- EEV is a trademark of the company.
- Job applications are handled through the Greenhouse hiring platform.
- It is a member of the Greater Boston Chamber of Commerce.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.